Initiator Pharma A/S (SE:INIT)
:INIT
Want to see SE:INIT full AI Analyst Report?
INIT Stock Chart & Stats
kr3.04
-kr0.20(-3.17%)
At close: 4:00 PM EST
kr3.04
-kr0.20(-3.17%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr4.17
Previous CloseN/A
Volume47.38K
Average Volume (3M)133.41K
Market Cap
kr180.72M
Enterprise Valuekr129.58M
Total Cash (Recent Filing)kr19.90M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineA narrowly focused, clinical-stage pipeline centered on sexual and reproductive health creates durable strategic clarity. Concentration on small-molecule candidates and defined indications can streamline clinical development decisions and make the assets more attractive for later-stage licensing or partnerships.
Modest Leverage And Positive EquityLow debt relative to equity provides financial flexibility and reduces bankruptcy risk while the company advances trials. Positive equity, though reduced, supports continued operations and gives management optionality for structured financing or partnering without being overlevered.
Improving Free Cash Flow DynamicsAn improvement in free cash flow versus the prior year shows progress toward better cash conversion and expense control. While still negative, this trend can reduce near-term financing needs and reflects incremental operational discipline as clinical programs advance.
Bears Say
No Revenue; Widening Net LossesPersistent lack of commercial revenue and materially larger net losses reduce internal funding capacity and extend dependency on external capital. Over the medium term, continued negative profitability undermines shareholder value unless offset by successful trials or non-dilutive partnering.
Sustained Cash Burn And Negative Operating Cash FlowConsistently negative operating cash flow indicates ongoing cash consumption to fund R&D and operations. This structural cash burn requires repeated financing rounds or licensing events, which can dilute equity or delay programs if capital access tightens.
Declining Equity And Funding/dilution RiskA marked decline in shareholders' equity over the last year signals value erosion from losses and heightens the probability of future equity raises. This structural funding risk can compress founder/ shareholder stakes and constrain long-term strategic choices.
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.53 and its highest was kr4.17 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr180.72M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 69 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.